Invesco Ltd. Acquires 760,579 Shares of CVS Health Corporation $CVS

Invesco Ltd. raised its holdings in CVS Health Corporation (NYSE:CVS) by 3.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 24,293,058 shares of the pharmacy operator’s stock after buying an additional 760,579 shares during the quarter. Invesco Ltd. owned 1.91% of CVS Health worth $1,831,454,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. bought a new stake in CVS Health in the 2nd quarter valued at $1,651,000. Allworth Financial LP increased its holdings in shares of CVS Health by 3.9% during the 2nd quarter. Allworth Financial LP now owns 26,842 shares of the pharmacy operator’s stock worth $1,852,000 after purchasing an additional 1,017 shares during the period. Boston Partners acquired a new position in shares of CVS Health during the second quarter valued at about $3,324,000. Jupiter Asset Management Ltd. bought a new stake in shares of CVS Health in the second quarter valued at about $7,512,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of CVS Health by 1.5% in the second quarter. PNC Financial Services Group Inc. now owns 568,176 shares of the pharmacy operator’s stock valued at $39,193,000 after buying an additional 8,407 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS from “market perform” to “outperform” and raised its price target to $94, increasing analyst conviction and suggesting ~23% upside vs. current levels. Read More.
• Positive Sentiment: CVS announced an AI-powered consumer health platform — a strategic push into digital care and personalization that could support margin expansion and higher patient engagement over time. Product rollout increases growth narrative beyond traditional retail/pharmacy. Read More.
• Positive Sentiment: Coverage of CVS investing in advanced consumer tech (“agentic twins”) signals ongoing R&D and digital transformation that investors often reward if it drives stickier customer relationships and services revenue. Read More.
• Neutral Sentiment: North Carolina’s health-plan contracting dynamics may trigger a competitive bidding environment for Aetna and CVS; this could create upside from new wins but also pressure on pricing depending on outcomes. Monitor contract renewals and win rates. Read More.
• Neutral Sentiment: Health-care sector weakness is a short-term headwind: the NYSE Health Care Index was modestly lower recently, which can pressure CVS alongside peers even when company-specific news is mixed. Read More.
• Neutral Sentiment: Market commentators note CVS is modestly down since its last earnings report — investors should focus on FY2026 guidance vs. consensus and upcoming catalysts that could re-rate the stock. Read More.
• Negative Sentiment: DOJ settlement: Aetna (CVS’s unit) agreed to a $117.7M settlement over alleged Medicare Advantage coding issues. While not crippling to cash flows, it is a near-term legal expense and adds regulatory scrutiny for Aetna’s Medicare business. Read More.
• Negative Sentiment: CVS says it may close 100+ Tennessee pharmacies in response to state PBM-related legislation — a politically charged dispute that could disrupt retail access, revenue in affected markets, and raise execution/PR risk if closures proceed. Read More.

Analyst Ratings Changes

CVS has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Barclays lifted their price objective on CVS Health from $87.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Mizuho boosted their price objective on CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Argus cut their target price on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Finally, UBS Group reiterated an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Stock Performance

NYSE CVS opened at $76.10 on Friday. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $85.15. The company has a 50 day moving average of $78.25 and a 200-day moving average of $77.71. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The firm has a market cap of $96.81 billion, a price-to-earnings ratio of 55.14, a PEG ratio of 0.79 and a beta of 0.49.

CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. During the same period in the previous year, the business earned $1.19 EPS. CVS Health’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio is presently 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.